Latest News

Latest News

How GLP-1 Drugs Are Reshaping Anesthesia Practice

How GLP-1 Drugs Are Reshaping Anesthesia Practice

Few classes of medications have changed the perioperative conversation as quickly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Originally developed primarily for the management of type 2 diabetes, GLP-1 therapy is now widely used for obesity and metabolic...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

The Sourcing Channel Moved East

The Sourcing Channel Moved East

A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...

read more
Parkinson’s Research Field is Approaching a Pivotal Moment

Parkinson’s Research Field is Approaching a Pivotal Moment

Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...

read more
The Emerging Health Tech Driving Globalised Healthcare

The Emerging Health Tech Driving Globalised Healthcare

Historically, healthcare has been reactive, defined largely by where a patient lives and what is available within their local system. That model is beginning to break down as healthcare becomes increasingly global. Patients are no longer confined to a single system,...

read more
PDUFA Date Explained: FDA Drug Approval Deadlines

PDUFA Date Explained: FDA Drug Approval Deadlines

Every time a pharmaceutical company submits a new drug to the US Food and Drug Administration, a clock starts. That clock ends on the PDUFA date. For anyone working in life sciences, whether in regulatory affairs, clinical research, investment, or commercial planning,...

read more
Weekly News Roundup | 1 June 2026

Weekly News Roundup | 1 June 2026

Life science news 1 June 2026: FDA approvals, a landmark obesity pill advance and a $10.5 billion Pfizer partnership define a milestone week for pharma and biotech. The week of 24 to 30 May 2026 delivered a string of significant regulatory milestones, high-value...

read more
The Underestimated Occupational Impact of Pelvic Pain

The Underestimated Occupational Impact of Pelvic Pain

When people think about pelvic pain, they often think about symptoms. Cramping. Heavy bleeding. Fatigue. Bloating. Pain during intimacy. Bladder urgency. What is discussed far less is the occupational impact of pelvic pain: the way pain changes a person’s ability to...

read more
Clinical Trials Roundup | 29 May 2026

Clinical Trials Roundup | 29 May 2026

Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...

read more
The Sourcing Channel Moved East

The Sourcing Channel Moved East

A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...

read more
Parkinson’s Research Field is Approaching a Pivotal Moment

Parkinson’s Research Field is Approaching a Pivotal Moment

Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...

read more
The Emerging Health Tech Driving Globalised Healthcare

The Emerging Health Tech Driving Globalised Healthcare

Historically, healthcare has been reactive, defined largely by where a patient lives and what is available within their local system. That model is beginning to break down as healthcare becomes increasingly global. Patients are no longer confined to a single system,...

read more
PDUFA Date Explained: FDA Drug Approval Deadlines

PDUFA Date Explained: FDA Drug Approval Deadlines

Every time a pharmaceutical company submits a new drug to the US Food and Drug Administration, a clock starts. That clock ends on the PDUFA date. For anyone working in life sciences, whether in regulatory affairs, clinical research, investment, or commercial planning,...

read more
Weekly News Roundup | 1 June 2026

Weekly News Roundup | 1 June 2026

Life science news 1 June 2026: FDA approvals, a landmark obesity pill advance and a $10.5 billion Pfizer partnership define a milestone week for pharma and biotech. The week of 24 to 30 May 2026 delivered a string of significant regulatory milestones, high-value...

read more
The Underestimated Occupational Impact of Pelvic Pain

The Underestimated Occupational Impact of Pelvic Pain

When people think about pelvic pain, they often think about symptoms. Cramping. Heavy bleeding. Fatigue. Bloating. Pain during intimacy. Bladder urgency. What is discussed far less is the occupational impact of pelvic pain: the way pain changes a person’s ability to...

read more
Clinical Trials Roundup | 29 May 2026

Clinical Trials Roundup | 29 May 2026

Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

The Silent Clock in Your Arteries

The Silent Clock in Your Arteries

The Silent Clock in Your Arteries: Why Vascular Aging Is the Heart Health Crisis We're Missing We are living in an era of extraordinary innovation in heart health. Precision diagnostics. AI-guided therapies. Wearables that track everything from rhythm to recovery. And...

read more
Kailera Therapeutics IPO: A $625M Signal for Biotech

Kailera Therapeutics IPO: A $625M Signal for Biotech

When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...

read more
Climate-Sensitive Maternal Mental Health Screening

Climate-Sensitive Maternal Mental Health Screening

A pregnant woman may never walk into a clinic saying climate change is affecting her mental health. She may say she has not slept through the heat. She may say flooding made her miss an antenatal visit. She may say food costs have changed what she can feed her family....

read more
Biotech’s Missing Ingredient: Execution

Biotech’s Missing Ingredient: Execution

Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

read more
Weekly News Roundup | 25 May 2026

Weekly News Roundup | 25 May 2026

Life science news 25 May 2026: Lilly's retatrutide delivers bariatric-surgery-level weight loss in Phase 3, two landmark FDA approvals reshape oncology and hepatology, and a UK biotech targets the global AMR crisis. The week of 17 to 24 May 2026 delivered a dense...

read more

Further News

Obesity Drug News: GLP-1 Readouts and Approval Watch

Last updated 25 October 2026 This page is the running record of obesity drug news at Life Science Daily News. It tracks what moved in the obesity and GLP-1 pipeline each month. Entries cover trial readouts, regulatory filings, approvals and label expansions. How this...

Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body

CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...

Genglycos Gene Therapy Approval Sets New Bar for Rare Metabolic Disease

The Genglycos gene therapy approval gives patients with glycogen storage disease type Ia a new option. The FDA describes it as the first approved treatment for the condition. It is designed to address the underlying cause. The US Food and Drug Administration granted...

AI-Discovered Drugs in 2026: The State of Play

Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...

Why Ingredient Research Is Only the Beginning of a Health Product

I spent years formulating low-carbohydrate, low-calorie, high-protein and gluten-free foods. That work taught me a lesson that is easy to miss when a new ingredient has exciting research behind it: an ingredient is not a finished product. A study can tell you that an...

Weekly News Roundup | 24 August 2026

Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...

The Role of Ambient AI in the Future of Specialty Care

For over a decade, the administrative burden in specialty medicine has quietly worsened. Orthopedic surgeons doing 40 patients a day are spending more time in the EHR than in the room. Ambient AI scribes have changed that equation in ways that are only beginning to...

Intismeran Autogene Phase 3 Win Moves Cancer Vaccines to Logistics

Merck and Moderna have reported what they describe as the first positive Phase 3 result for an individualised cancer therapy. Intismeran autogene, given with pembrolizumab, met its primary endpoint in resected melanoma. The companies announced the outcome on 19 August...

APAC Biopharma in 2026: Asia’s Shift From Supplier to Source

APAC biopharma has stopped being a cost line in somebody else’s budget. For two decades the region supplied ingredients, capacity and inexpensive trial sites. The companies that used them were headquartered elsewhere. That relationship has now inverted. The clearest...

Beyond the Benchmark: A Four-Layer Framework for Evaluating Healthcare AI

Healthcare AI is often evaluated where it is easiest to measure: on a dataset. Accuracy, sensitivity, specificity, calibration, retrieval quality, hallucination rates and task-completion scores all matter. But they answer only the first question: can the model perform...

The Next Era of Cardiorenal Care Is Precision Fluid Management

Medicine has become increasingly specialized over the past several decades, driving tremendous advances in our ability to diagnose and treat complex diseases. Specialists now possess deeper expertise than ever before, allowing clinicians to deliver highly targeted...

Clinical Trials Roundup | 21 Aug 2026

Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.